Loading data for ABUS — first visit, this takes a few seconds.

Alert

Arbutus Biopharma Corpora... (ABUS)

NasdaqGS: ABUS · Real-Time Price · USD

5.20

+0.00 (0.00%)

At close: Aug 25, 2026, 3:01 PM

The price, the headline numbers and the latest news, in one place.

0.00% (1D)

Bid	3.73
Market Cap	1.03B
Revenue (ttm)	181.72M
Net Income (ttm)	153.05M
	0.60
	0.79
	6.58
	-31.43
P/B (ttm)	3.97
P/S (ttm)	5.66
Earnings Date	Nov 16, 2026

Ask	6.59
Volume	5,743,621
Avg. Volume (20D)	2,536,641
Open	5.25
Previous Close	5.20
Day's Range	5.13 - 5.26
52-Week Range	3.50 - 5.45
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About ABUS

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Jul 26, 2007

Employees 19

Stock Exchange NasdaqGS

Ticker Symbol ABUS

Website https://www.arbutusbio.com

Full Company Profile

Financial Performance

In 2025, Arbutus Biopharma's revenue was 14.08M, an increase of 128.21% compared to the previous year's 6.17M. Earnings were -33.5M, a decrease of -52.09%.

Financial Statements

Earnings Surprise

Arbutus Biopharma has released their quarterly earnings on Aug 12, 2026:

Revenue of $179.13M misses estimates by $0, with 10054.54% YoY growth.
EPS of -0.04 misses estimates by -0.01, with -500.00% YoY decline.

Next Earnings Release

Arbutus Biopharma Corporation is scheduled to release its earnings on Nov 16, 2026, before market opens.
Analysts project revenue of ... Upgrade

News

3 days ago · MT Newswires

Sector Update: Healthcare Stocks Advance in Afternoon Trading

Healthcare stocks were higher Friday afternoon, with the NYSE Healthcare Index rising 1.4% and the S

4 days ago · InvestorsHub

Arbutus Biopharma shares jump after unveiling $230 million share buyback plan

Arbutus Biopharma Corporation (NASDAQ:ABUS) shares climbed 10. 3% in premarket trading on Friday after the biotechnology company announced plans to repurchase up to $230 million of its common stock th...

4 days ago · Stocktwits

ABUS Stock Surges 10% Today — What’s Driving This Super Rally?

Arbutus Biopharma said it will repurchase $230 million of its common shares at a purchase price of not less than $5 per share and not more than $5.75 apiece, in cash.

5 days ago · 24/7 Wall St.

Moderna’s Newfound War Chest Opens Door for 4 Strategic Acquisition Targets

Moderna's stock just surged in a way that transforms the company from a cash-burning vaccine maker into a serious acquirer, and four biotech targets already sit within striking range of its newly load...

2 weeks ago · Insider Monkey

Could Arbutus Biopharma Corporation (ABUS) Turn its Moderna, Inc. (MRNA) Settlement Into a Lasting Biotech Advantage?

A landmark legal settlement in the biotech sector recently reshaped the financial trajectories of two key mRNA technology players: Arbutus Biopharma Corporation (NASDAQ:ABUS) and Moderna, Inc. (NASDAQ...

Page 1 of 2